The 25 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 66.84, with a high estimate of 73.61 and a low estimate of 32.87. The median estimate represents a +4.21% increase from the last price of 64.14.
The current consensus among 28 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.68
Reporting Date May 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.